More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.
You may also be interested in...
Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.